BofA analyst Jason Zemansky lowered the firm’s price target on Werewolf Therapeutics (HOWL) to $8 from $9 and keeps a Buy rating on the shares, citing the current cash position for the firm’s revised target after a Q2 report that “didn’t have many major updates.” The firm still sees reasons to like the the second half setup with opportunities for a potential re-rating, the analyst tells investors.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HOWL:
- Werewolf Therapeutics price target lowered to $3 from $4 at Citizens JMP
- Promising Advancements in Werewolf Therapeutics’ Drug Pipeline Support Buy Rating
- Werewolf Therapeutics Faces Regulatory and Financial Challenges Amid FDA Disruptions
- Werewolf Therapeutics Reports Q2 2025 Financial Results
- Werewolf Therapeutics sees cash runway into 4Q26